Liver Transplantation Clinical Trial
Official title:
Enteric Coated Mycophenolic Acid (Myfortic) in Liver Transplant Recipients- Effect on Compliance and Calcineurin Inhibitor and Corticosteroid Sparing
The purpose of this study is to replace the mycophenolate mofetil (Cellcept) which is our usual therapy after liver transplantation with sodium mycophenolic acid (Myfortic®) and to find out the effect this change may have on the development of side effects such as relief of gastrointestinal (stomach) problems. In the past we have had to stop Cellcept (our current drug) because of these side effects. We will also try to see if improved usage of this drug (Myfortic®) will allow us to use lower doses of other medications that lower your immune system. We will do some special tests on your blood to see if the amount of the drug is related with its effect on the immune system and side effects. Both Cellcept and Myfortic® are FDA approved medications although Myfortic® is not approved for use after liver transplantation. Myfortic® is really the same active drug as Cellcept® (Mycophenolic acid) but has been coated to prevent breakdown of the drug in the stomach and is made to lower the known gastrointestinal effects of Cellcept such as diarrhea, abdominal pain and nausea.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | February 2009 |
Est. primary completion date | February 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Liver transplant recipients - Age: 18-70 - Capable of oral intake Exclusion Criteria: - Hepatitis C Cirrhosis - Hepatocellular Carcinoma T3 - Liver retransplantation - Pregnancy - Platelet count <40,000 - White Blood Cell count (WBC) <3,000 - Incapable of oral intake - More than 30 days post op |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Hermann Hospital | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Health Science Center, Houston | Novartis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of rejection | 6 months | Yes | |
Primary | Rate of gastrointestinal side-effects | 6 months | Yes | |
Secondary | Levels of calcineurin inhibitors | 6 months | No | |
Secondary | Renal function | 6 months | Yes | |
Secondary | Relationship of dose to biologic monitoring of immunosuppression | 6 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Completed |
NCT00170131 -
MMF Influence on HCV Viral Evolution After Liver Transplantation
|
Phase 4 |